First, in NSCLC, NGS identifies driver mutations (e.g., EGFR, ALK, and ROS1) that guide tyrosine kinase inhibitor (TKI) therapy, yielding substantially improved progression-free survival relative to conventional chemotherapy [97]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.